Live Breaking News & Updates on Hepalys Pharma|Page 5

Stay updated with breaking news from Hepalys pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea -September 20, 2023 at 04:01 pm EDT

Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million. ....

United States , New York , San Francisco , South Korea , South Koreans , South Korean , Aude Lepreux , Catalys Pacific , Nonliver Comorbidities , Hepalys Pharma , Pascaline Clerc , Hepalys Pharma Inc , Global External Affairs , Exchange Commission On , Brunswick Group , Mitsubishi Ufj , Innovation Fund , Patricial Bank , Hepalys Pharma Inc We , Long Island City , Euronext Paris , Greater China , Representative Director , Breakthrough Therapy , Fast Track , Nasdaq Global Market ,

Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea - Inventiva (OTC:IVEVF), Inventiva (NASDAQ:IVA)

Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million upfront payment, and is ....

New York , United States , San Francisco , South Korea , South Koreans , South Korean , Hepalys Pharma , Nonliver Comorbidities , Catalys Pacific , Innovation Fund , Hepalys Pharma Inc We , Mitsubishi Ufj , Exchange Commission On , Hepalys Pharma Inc , Long Island City , Greater China , Representative Director , Breakthrough Therapy , Fast Track , Euronext Paris , Nasdaq Global Market , Private Securities Litigation Reform Act , New Drug Application , Universal Registration Document , Des March , Annual Report ,